Understand any stock in simple English
Amicus Therapeutics develops and sells medicines for rare and orphan diseases.
Amicus Therapeutics is a rare-disease drugmaker. It focuses on illnesses that few people have, which means big pharma often ignores them, but those patients still need treatment and are willing to pay for it. Amicus builds medicines for a handful of these conditions, mostly genetic disorders where the body is missing or misusing an important protein.
Its best-known business is a drug for Fabry disease, a genetic condition where a fatty substance builds up in cells and damages organs like the heart and kidneys. The drug works by helping the body's own faulty protein do its job better, rather than just replacing what's missing. Amicus also sells a therapy for Pompe disease, another rare muscle-wasting disorder, and it has been developing treatments for other rare conditions. The company earns money by selling these medicines, largely in the United States and Europe, and patients typically stay on them for life. What makes this kind of business attractive is that rare-disease drugs face little competition, command high prices, and win long-lasting patent protection and special regulatory incentives. The flip side is that each disease has so few patients that the market is small, and developing a new drug is expensive and risky. Amicus has poured money into research and deals to broaden its pipeline, and it has leaned on partnerships and outside funding to keep that engine running.
The company's shares once traded on the Nasdaq under the ticker FOLD, but they no longer trade publicly. Ownership now sits with private investors rather than public shareholders. For a small rare-disease specialist, that shift matters: going private can mean more patience and less quarterly pressure while it spends heavily on new treatments.
Saved answer · last researched 17 Nov 2026